$ Value
$0
Shares
157,500
Price
$0
Filed
Sep 22
Insider
Name
Stewart Richard Alistair
Title
Chief Executive Officer
CIK
0001713369
Roles
Transaction Details
Transaction Date
2025-09-18
Code
M
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
—
Footnotes
Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. | Represents shares of common stock that have been sold by the Reporting Person to satisfy income tax withholding and remittance obligations in connection with the net settlement of the PRSUs. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.83 to $3.02 per share, inclusive. The reporting person hereby undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The reporting holder is the principal owner of Ricanto Limited. | Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. | Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones.
Filing Info
Stewart Richard Alistair's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-01-28 | ACHV | A | $0 |
| 2025-09-18 | ACHV | M | $0 |
| 2025-09-18 | ACHV | ▼ | $378K |
| 2025-09-18 | ACHV | M | $0 |
| 2025-09-18 | ACHV | M | $0 |
| 2025-09-04 | ACHV | A | $0 |
| 2025-09-04 | ACHV | A | $0 |
Other Insiders at ACHV (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Oki Mark K
Chief Financial Officer
|
— | — | 2026-01-28 |
|
Stewart Richard Alistair
Chief Executive Officer
|
— | — | 2026-01-28 |
|
Goldberg Andrew D.
CEO and President
|
— | — | 2026-04-18 |
|
Wan Jerry
Principal Accounting Officer
|
— | — | 2026-01-28 |
|
Xinos Jaime
Chief Commercial Officer
|
— | — | 2026-01-28 |
|
Donnelly Craig
Chief Operations Officer
|
— | — | 2026-01-28 |
|
Rubinstein Mark Lawrence
Chief Medical Officer
|
— | — | 2026-01-28 |